(Q37051456)

17 August 2017

1 reference

title

Resistant hypertension and aldosteronism (English)

1 reference

17 August 2017

main subject

arterial hypertension

0 references

author name string

Eduardo Pimenta

series ordinal

1

1 reference

17 August 2017

David A Calhoun

series ordinal

2

1 reference

17 August 2017

publication date

1 November 2007

1 reference

Current Hypertension Reports

17 August 2017

published in

1 reference

17 August 2017

volume

9

1 reference

17 August 2017

issue

5

1 reference

17 August 2017

page(s)

353-359

1 reference

https://scigraph.springernature.com/pub.10.1007/s11906-007-0066-7

17 August 2017

exact match

0 references

cites work

Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio

1 reference

https://api.crossref.org/works/10.1007%2FS11906-007-0066-7

Aldosterone induces a vascular inflammatory phenotype in the rat heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-007-0066-7

Changes in left ventricular anatomy and function in hypertension and primary aldosteronism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-007-0066-7

Primary aldosteronism: factors associated with normalization of blood pressure after surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-007-0066-7

Hyperaldosteronism among black and white subjects with resistant hypertension

21 January 2018

1 reference

12 December 2020

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

1 reference

12 December 2020

Validity of plasma aldosterone-to-renin activity ratio in African American and white subjects with resistant hypertension

1 reference

12 December 2020

The evolution of primary aldosteronism: 1954-1967

1 reference

12 December 2020

Low-dose spironolactone in the management of resistant hypertension: a surveillance study

1 reference

12 December 2020

Mineralocorticoid excess, dietary sodium, and myocardial fibrosis

1 reference

12 December 2020

Resistant hypertension revisited: a comparison of two university-based cohorts.

1 reference

12 December 2020

Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism

1 reference

12 December 2020

Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region.

1 reference

12 December 2020

Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT).

1 reference

12 December 2020

Primary hyperaldosteronism: effect of adrenal vein sampling on surgical outcome

1 reference

12 December 2020

Efficacy of low-dose spironolactone in subjects with resistant hypertension

1 reference

12 December 2020

A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial

1 reference

12 December 2020

Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome.

1 reference

12 December 2020

Hypertension as a hemodynamic disease: the role of impedance cardiography in diagnostic, prognostic, and therapeutic decision making

1 reference

12 December 2020

Low-renin status in therapy-resistant hypertension: a clue to efficient treatment

1 reference

12 December 2020

Impaired endothelium-dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteronism

1 reference

12 December 2020

Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000.

1 reference

12 December 2020

Evidence that primary aldosteronism may not be uncommon: 12% incidence among antihypertensive drug trial volunteers

1 reference

12 December 2020

Does aldosterone-to-renin ratio predict the antihypertensive effect of the aldosterone antagonist spironolactone?

1 reference

12 December 2020

Primary aldosteronism: diagnostic and treatment strategies

1 reference

12 December 2020

Primary aldosteronism and hypertensive disease

1 reference

12 December 2020

The role of spironolactone in the treatment of patients with refractory hypertension

1 reference

12 December 2020

Aldosterone-induced organ damage: plasma aldosterone level and inappropriate salt status

1 reference

12 December 2020

High incidence of primary aldosteronism in 199 patients referred with hypertension

1 reference

12 December 2020

Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension

1 reference

12 December 2020

Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients

1 reference

12 December 2020

Multidisciplinary vascular screening program modestly improves the medical treatment of vascular risk factors

1 reference

12 December 2020

Cross-sectional relations of serum aldosterone and urine sodium excretion to urinary albumin excretion in a community-based sample

1 reference

12 December 2020

Effect of spironolactone on blood pressure in subjects with resistant hypertension

1 reference

12 December 2020

10.1007/S11906-007-0066-7

Identifiers

DOI

1 reference

17 August 2017

1 reference